Research on nonprescription depression products is unevenly distributed
A review of 209 trials mapped uneven evidence for nonprescription products used for depressive symptoms; evidence volume does not establish which product works best.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
For adults with depressive symptoms or a depression diagnosis, this review mapped research on nonprescription products rather than identifying a best treatment. Evidence was concentrated in a few products, while many others had sparse research. Descriptions of promising evidence, without effect estimates, leave both effectiveness and safety questions unresolved.
Products were described as promising without product-specific effect estimates. The abstract also omits the trial comparators and follow-up periods, so it cannot show which products work best or whether effects persist.
Evidence volume versus effectiveness
Omega-3 products, St John's wort, saffron, probiotics and vitamin D had the largest bodies of research. This describes how much they have been studied, rather than a direct comparison of their effects.
Sparse evidence and safety reporting
For 41 products, the review found only a single trial. Safety reporting also needed improvement, so few reported safety problems should not be treated as proof that all of these products are safe.
The original publication
Understanding the research landscape of over-the-counter herbal products, dietary supplements, and medications evaluated for depressive symptoms in adults: a scoping review.
Frost R, Zamri A, Mathew S et al.
Front Pharmacol · 2025
- PubMed ID
- 40735481
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.